AstraZeneca (NYSE:AZN) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS
AstraZeneca (NYSE:AZN) released its quarterly earnings data on Thursday. The company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.04, MarketWatch Earnings reports. AstraZeneca had a net margin of 8.36% and a return on equity of 37.83%. The business had revenue of $6.28 billion during the quarter, compared to analyst estimates of $6.27 billion. During the same period in the previous year, the business earned $0.73 EPS. AstraZeneca’s revenue was up 9.7% compared to the same quarter last year.
Shares of AstraZeneca stock traded down $2.11 during trading on Friday, reaching $55.78. 6,844,544 shares of the stock were exchanged, compared to its average volume of 10,823,646. AstraZeneca has a 1 year low of $36.15 and a 1 year high of $64.94. The firm has a market cap of $146.39 billion, a price-to-earnings ratio of 67.20, a price-to-earnings-growth ratio of 1.71 and a beta of 0.55. The company has a quick ratio of 0.57, a current ratio of 0.75 and a debt-to-equity ratio of 1.32. The stock’s fifty day moving average is $54.53 and its 200 day moving average is $50.30.
The company also recently disclosed a semi-annual dividend, which will be paid on Monday, September 14th. Stockholders of record on Friday, August 14th will be paid a dividend of $0.45 per share. This represents a dividend yield of 2.5%. The ex-dividend date of this dividend is Thursday, August 13th. AstraZeneca’s dividend payout ratio (DPR) is 106.29%.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: Cash Flow
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.